Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies

Gennaro Pagano; Flavia Niccolini; Paolo Fusar-Poli; Marios Politis

doi:10.1002/ana.24859

Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies

Gennaro Pagano, Flavia Niccolini, Paolo Fusar-Poli, Marios Politis^*

^*Corresponding author for this work

KCH King's College Hospital NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

74 Citations (Scopus)

699 Downloads (Pure)

Abstract

Positron emission tomography (PET) is a powerful analytical tool for in vivo molecular imaging of the human brain. Over the past years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided evidence for the key role of serotonergic pathology in patients with Parkinson's disease (PD). Here, we review the role of SERT in the development of motor and nonmotor complications in patients with PD, and we performed a meta-analysis to identify the patterns of SERT pathology and the relevance to symptoms. Consistent SERT pathology in raphe nuclei, striatum, thalamus, and hypothalamus and associations with aging, PD progression, development of dyskinesias, and cognitive decline were observed. Ann Neurol 2017;81:171–180.

Original language	English
Pages (from-to)	171-180
Number of pages	10
Journal	Annals of Neurology
Volume	81
Issue number	2
Early online date	26 Dec 2016
DOIs	https://doi.org/10.1002/ana.24859
Publication status	Published - 23 Feb 2017

Keywords

DASB
PET
Parkinson's Disease
Meta-analyses

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ana.24859

Serontin transporter in Parkinson's disease_PAGANO_Accepted22December2016_GREEN AAMAccepted author manuscript, 560 KB

Cite this

@article{e9e5f31f5b3e44a89eb878a89dab7f0d,

title = "Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies",

abstract = "Positron emission tomography (PET) is a powerful analytical tool for in vivo molecular imaging of the human brain. Over the past years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided evidence for the key role of serotonergic pathology in patients with Parkinson's disease (PD). Here, we review the role of SERT in the development of motor and nonmotor complications in patients with PD, and we performed a meta-analysis to identify the patterns of SERT pathology and the relevance to symptoms. Consistent SERT pathology in raphe nuclei, striatum, thalamus, and hypothalamus and associations with aging, PD progression, development of dyskinesias, and cognitive decline were observed. Ann Neurol 2017;81:171–180.",

keywords = "DASB, PET, Parkinson's Disease, Meta-analyses",

author = "Gennaro Pagano and Flavia Niccolini and Paolo Fusar-Poli and Marios Politis",

year = "2017",

month = feb,

day = "23",

doi = "10.1002/ana.24859",

language = "English",

volume = "81",

pages = "171--180",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Serotonin transporter in Parkinson's disease

T2 - A meta-analysis of positron emission tomography studies

AU - Pagano, Gennaro

AU - Niccolini, Flavia

AU - Fusar-Poli, Paolo

AU - Politis, Marios

PY - 2017/2/23

Y1 - 2017/2/23

N2 - Positron emission tomography (PET) is a powerful analytical tool for in vivo molecular imaging of the human brain. Over the past years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided evidence for the key role of serotonergic pathology in patients with Parkinson's disease (PD). Here, we review the role of SERT in the development of motor and nonmotor complications in patients with PD, and we performed a meta-analysis to identify the patterns of SERT pathology and the relevance to symptoms. Consistent SERT pathology in raphe nuclei, striatum, thalamus, and hypothalamus and associations with aging, PD progression, development of dyskinesias, and cognitive decline were observed. Ann Neurol 2017;81:171–180.

AB - Positron emission tomography (PET) is a powerful analytical tool for in vivo molecular imaging of the human brain. Over the past years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided evidence for the key role of serotonergic pathology in patients with Parkinson's disease (PD). Here, we review the role of SERT in the development of motor and nonmotor complications in patients with PD, and we performed a meta-analysis to identify the patterns of SERT pathology and the relevance to symptoms. Consistent SERT pathology in raphe nuclei, striatum, thalamus, and hypothalamus and associations with aging, PD progression, development of dyskinesias, and cognitive decline were observed. Ann Neurol 2017;81:171–180.

KW - DASB

KW - PET

KW - Parkinson's Disease

KW - Meta-analyses

UR - http://www.scopus.com/inward/record.url?scp=85013638025&partnerID=8YFLogxK

U2 - 10.1002/ana.24859

DO - 10.1002/ana.24859

M3 - Article

AN - SCOPUS:85013638025

SN - 0364-5134

VL - 81

SP - 171

EP - 180

JO - Annals of Neurology

JF - Annals of Neurology

IS - 2

ER -

Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this